Apr 2, 2020 SOURCE: PR NewsWire
AbbVie Inc. - Form 8.1 - Dealings By Offerors, Offerees Or Parties Acting In Concert With Them For Themselves Or For Discretionary Clients
NORTH CHICAGO, Ill., April 2, 2020 /PRNewswire/ --
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1.
KEY
INFORMATION
Name of person dealing (Note 1)
Edward Liddy
--- ---
Company dealt in
AbbVie Inc.
--- ---
Class of relevant security to which the dealings being disclosed relate (Note 2)
Common shares, par value $0.01 per share
--- ---
Date
of
dealing
31 March 2020
--- ---
2.
INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
---
(1) Relevant securities 22,669 (0.002%)
---
(2)
Derivatives
(other
than
options) 25,118 (0.002%)
---
(3) Options and agreements to purchase/sell N/A
---
Total 47,787 (0.003%)
---
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security: Long Short
---
Number (%)
Number (%)
---
(1) Relevant securities
---
(2)
Derivatives
(other
than
options)
---
(3) Options and agreements to purchase/sell
---
Total
---
3.
DEALINGS (Note 4)
(a) Purchases and sales
Purchase/
sale
Number of relevant securities
Price per unit (Note 5)
--- ---
(b) Derivatives transactions (other than options transactions)
Product name,
Nature of transaction
Number of relevant securities
Price per unit
e.g.
CFD
(Note 6)
(
Note 7) (Note 5)
--- ---
Stock equivalent unit Director fee credit to stock equivalent unit account 426 $76.19
--- ---
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing,
selling,
purchasing, Number
of
securities
to Exercise
price Type,
e.g.
American, Expiry
date Option
money
paid/received
per
name, varying etc. which
the
option
relates (Note 7) European etc. unit (Note 5)
e.g.
call
option
--- ---
(ii) Exercising
Product name,
e.g. call option
Number of securities
Exercise price per unit (Note 5)
--- ---
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature
of Price
per
unit
transaction
(if applicable) (Note 5)
(Note 8)
Details
--- ---
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any
derivative referred to on this form is referenced. If none, this should be stated.
---
Is a Supplemental Form 8 attached? (Note 9) YES/NOSQRT
Date of disclosure
2 April 2020
--- ---
Contact
name Steven L. Scrogham
--- ---
Telephone
number
847-938-6166
--- ---
Name
of
offeree/offeror
with
which
acting
in
concert
AbbVie Inc.
--- ---
Specify category and nature of acting in concert status Director of AbbVie Inc.
--- ---
View original content:http://www.prnewswire.com/news-releases/abbvie-inc---form-8-1---dealings-by-offerors-offerees-or-parties-acting-in-concert-with-them-for-themselves-or-for-discretionary-clients-301034599.html
SOURCE AbbVie
